New Dual-Action Lupus Drug Shows Promising Results in Phase III Trial — A Game Changer for SLE Treatment?
Susan Hendrix • October 21, 2025
A closer look at Telitacicept, the innovative fusion protein targeting BLyS and APRIL, and what its success could mean for the future of lupus care.
The body content of your post goes here. To edit this text, click on it and delete this default text and start typing your own or paste your own from a different source.